Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Vericel Corp VCEL

Healthcare Biotechnology
Vericel Corporation is a fully-integrated, commercial-stage biopharmaceutical company. The Company is a provider of advanced therapies for the sports medicine and severe burn care markets. It markets three products in the United States. MACI (autologous cultured chondrocytes on porcine collagen membrane) is an autologous-cellularized scaffold product indicated for the repair of symptomatic... see more

Recent & Breaking News (NDAQ:VCEL)

Vericel to Present at Canaccord Genuity Investor Conference

GlobeNewswire February 24, 2016

Vericel Announces FDA Approval of Epicel HDE Supplement

GlobeNewswire February 22, 2016

Vericel Submits Biologics License Application to the FDA for MACI for the Treatment of Cartilage Defects in the Knee

GlobeNewswire January 4, 2016

Vericel Submits HDE Supplement to the FDA to Revise the Labeled Indications for Use and Add Pediatric Labeling for Epicel

GlobeNewswire December 8, 2015

Cesca's Unique Approach to Regenerative Medicine - a Razor-Razor Blade Business Model

Accesswire November 19, 2015

Vericel Reports Third-Quarter 2015 Financial Results

GlobeNewswire November 13, 2015

Vericel to Host Third-Quarter 2015 Earnings Webcast and Conference Call on November 13, 2015

GlobeNewswire November 3, 2015

Vericel Announces Long-Term Supply Agreement With Matricel for Key Component of MACI(TM)

Marketwired October 26, 2015

Vericel to Present at Upcoming Investor Conferences

GlobeNewswire September 23, 2015

Vericel Reports Second-Quarter 2015 Financial Results

GlobeNewswire August 12, 2015

Vericel to Host Second-Quarter 2015 Earnings Webcast and Conference Call on August 12, 2015

GlobeNewswire July 29, 2015

Vericel to Host Second-Quarter 2015 Earnings Webcast and Conference Call on August 12, 2015

GlobeNewswire July 29, 2015

Vericel Announces Plan to Submit HDE Supplement to the FDA to Revise the Labeled Indications for Use and Add Pediatric Labeling for Epicel

GlobeNewswire July 14, 2015

Vericel Announces Plan to Submit Biologics License Application to FDA by Year-End 2015 for MACI for the Treatment of Cartilage Defects in the Knee

GlobeNewswire June 10, 2015

Vericel Reports First-Quarter 2015 Financial Results

GlobeNewswire May 14, 2015

Vericel to Host First-Quarter 2015 Earnings Webcast and Conference Call on May 14, 2015

GlobeNewswire April 30, 2015

Vericel to Present at Needham Healthcare Conference

GlobeNewswire April 8, 2015

Vericel Reports Three-Year Follow-Up Results From Phase 3 SUMMIT Extension Study of MACI(TM) Implant

GlobeNewswire March 25, 2015

Vericel Reports Fourth-Quarter and Year-End 2014 Financial Results

GlobeNewswire March 23, 2015

Vericel to Present at Canaccord Genuity and ARM Investor Conferences

GlobeNewswire March 18, 2015